Published online Sep 15, 2015. doi: 10.4251/wjgo.v7.i9.141
Peer-review started: April 2, 2015
First decision: April 23, 2015
Revised: June 3, 2015
Accepted: July 18, 2015
Article in press: July 22, 2015
Published online: September 15, 2015
Core tip: Radiotherapy is commonly offered to patients with pancreatic malignancies although its ultimate utility is compromised since the pancreas is surrounded by exquisitely radiosensitive normal tissues, such as the duodenum, stomach, jejunum, liver, and kidneys. Proton radiotherapy can be used to create dose distributions that conform to tumor targets with significant normal tissue sparing. Because of this, protons appear to represent a superior modality for radiotherapy delivery to patients with unresectable tumors and those receiving postoperative radiotherapy. A particularly exciting opportunity for protons also exists for patients with resectable and marginally resectable disease.